Pediatric Subjects with Acute Bacterial Skin and Skin Structure Infections

Status: open

A Phase 3, Multicenter, Open-Label, Randomized, Comparator Controlled Trial of the Safety and Efficacy of Dalbavancin versus Active Comparator in Pediatric Subjects with Acute Bacterial Skin and Skin Structure Infections

Treatment for Pediatric Skin Infection

Contact Us Or call 251-415-1598

Description

To determine the safety and descriptive efficacy of dalbavancin for the treatment of acute bacterial skin and skin structure infections in children, aged 3 months to 17 years, known or suspected to be caused by susceptible Gram-positive organisms, including methicillin-resistant strains of Staphylococcus aureus.

Sponsors

This trial is sponsored by Durata Therapeutics.

Providers Associated With This Trial

Principle Investigator

Sub Investigators

This link will open in a new tab or window.